On the stock market since 1986, it operates in the world of health and science. It has 14 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $48.6M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
The net profit margin is 61% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 105% a year on average.
It pays out $2.16 per share each year — regular cash for whoever holds the stock.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 37/100.
On our five-subject report card, XOMA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: XOMA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.